



Joe Lombardo  
Governor

# NEVADA HEALTH AUTHORITY

## Nevada Medicaid

4070 Silver Sage Drive  
Carson City, NV 89701

[NVHA.NV.GOV](http://NVHA.NV.GOV)



Stacie Weeks, Director

Ann Jensen, Administrator

## Drug Utilization Review Board Meeting Minutes

**Date of Meeting:** January 15, 2026

**Name of Organization:** The State of Nevada, Nevada Health Authority, Nevada Medicaid, Drug Use Review Board

Agenda Item	Record	Notes																					
1) Call to Order and Roll Call	<p>It was announced the meeting is being recorded.</p> <p>Chairperson Jennifer Wheeler called the meeting to order at 1:04 p.m. on 01/15/2026.</p> <p>Chairperson Wheeler took the roll.</p> <table> <tr> <th></th><th>Present</th><th>Absent</th></tr> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• David England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> </table>		Present	Absent	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• David England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<p><b>Nevada Medicaid Staff Present were as follows:</b></p> <ul style="list-style-type: none"> <li>• Duncan, Keiko, Pharm.D Senior Clinical &amp; Pharmacy Officer</li> <li>• Brown, Antonio, Chief of Pharmacy</li> <li>• Palomino, Bonnie, Pharmacy Services Manager</li> <li>• Cabrera, Donna, Program Officer I</li> <li>• Gonzalez, Taylor- Rae, Program Specialist II</li> </ul> <p><b>Prime Therapeutics Staff Present were as follows:</b></p> <ul style="list-style-type: none"> <li>• Czechowski, Jessica, Pharm.D., Director, Clinical Account Services</li> <li>• Mishra, Raj, Pharm.D., Clinical Account Manager</li> <li>• Deoliveira, Brittany, Pharm.D., Clinical Account Manager</li> <li>• Martinez, Chris, Sr. Business Analyst</li> <li>• Facchini, Victoria, Pharm.D., Director, Specialty Clinical Solutions</li> </ul>
	Present	Absent																					
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																					
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																					
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																					
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																					
• David England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																					
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																					

		<p><b>Managed Care Organization representatives present were as follows:</b></p> <ul style="list-style-type: none"><li>• Crecco, Jason, Pharm.D., Health Plan of Nevada</li><li>• Beranek, Tom, Pharm.D., Silver Summit Health Plan</li><li>• Tran, Jimmy, Pharm.D., Molina Healthcare</li><li>• Izuora, Kodi, Pharm.D., Anthem</li><li>• Rogina, Kreshmir, Pharm.D., CareSource</li></ul> <p><b>The public attendee list is included as Attachment A.</b></p> <p><b>Note:</b> Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list’s accuracy is not assured.</p>												
<b>2) General Public Comment</b>	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>													
<b>3) Administrative</b>														
<b>a) For Possible Action:</b> Review and Approve Meeting Minutes from October 16, 2025.	<p>Vice Chair Netochi Adeolokun moved to approve the minutes as presented, and Chairperson Wheeler seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.											
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											

	<ul style="list-style-type: none"> <li>• Crystal Castaneda, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Jessica Cate, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• David England, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> </ul>	
<b>b) Status Update by NVHA</b>	<p>Senior Clinical &amp; Pharmacy Officer Dr. Keiko Duncan provided an announcement:</p> <p>Exciting update is that MCO plans and Fee-For-Service program have moved to our Single Preferred Drug List.</p> <p>That went live on January 1<sup>st</sup>. We are in the process of transitioning to ensure that for any patients that were on medications that are now not currently formulary, we do have a method for them to still receive those medications for the time being. But the Single Preferred Drug List is now live, which is probably the most exciting piece of information.</p> <p>We always announce that we are recruiting for both of our boards, especially if you are a physician, physician assistant, APRN, or pharmacist. If you're interested, please check out our website or e-mail us at <a href="mailto:rxinfo@nvha.nv.gov">rxinfo@nvha.nv.gov</a>.</p>	

<b>4) Clinical Presentations</b>		
a) <b>For Possible Action:</b> Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>Hereditary Angioedema Agents</b> .		
i) <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>	
ii) Presentation of utilization and clinical information.	<p>Dr. Raj Mishra reviewed the proposed criteria presented in the binder for Hereditary Angioedema Agents.</p> <ul style="list-style-type: none"> <li>• Dr. Jason Crecco with Health Plan of Nevada presented the drug utilization.</li> <li>• Dr. Tom Beranek with Silver Summit Health Plan presented the drug utilization.</li> <li>• Dr. Jimmy Tran with Molina Healthcare presented the drug utilization.</li> <li>• Dr. Kodi Izuora with Anthem presented the drug utilization.</li> </ul>	
iii) Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked if the board members had any comments.</p> <p>No comments were made.</p>	

iv) Proposed adoption of updated prior authorization criteria.	<p>Board Member David England moved to approve the criteria as presented by Prime Therapeutics, and Board Member Jim Tran seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• David England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• David England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• David England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
b) <b>For Possible Action:</b> Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>Spevigo (spesolimab-sbzo)</b> .																														
i) <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>Public comment was provided by Valerie Ng Pharmacist and part of Medical Affairs at Leo Pharma for Spevigo.</p>																													
ii) Presentation of utilization and clinical information.	<p>Dr. Mishra reviewed the proposed criteria presented in the binder for Spevigo.</p> <ul style="list-style-type: none"><li>• Dr. Jason Crecco with Health Plan of Nevada presented the drug utilization.</li><li>• Dr. Tom Beranek with Silver Summit Health Plan presented the drug utilization.</li><li>• Dr. Jimmy Tran with Molina Healthcare presented the drug utilization.</li><li>• Dr. Kodi Izuora with Anthem presented the drug utilization.</li></ul>																													

iii) Discussion by Board and review of utilization data.	Chairperson Wheeler asked if the board members had any comments.  No public comment was provided.																													
iv) Proposed adoption of updated prior authorization criteria.	Vice Chair Adeolokun moved to approve the criteria as presented by Prime Therapeutics, and Board Member England seconded the motion.  A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):  <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
c) <b>For Possible Action:</b> Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>Respiratory and Allergy Biologics</b> .																														
i) <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comments were called for, and the phone lines were opened.  Public comment was provided by Kristin Duffey Pharmacist and Value Evidence Lead with Novartis, and today I will be speaking on behalf of Rhapsido.																													

ii) Presentation of utilization and clinical information.	<p>Dr. Mishra reviewed the proposed criteria presented in the binder for Respiratory and Allergy Biologics.</p> <ul style="list-style-type: none"><li>• Dr. Jason Crecco with Health Plan of Nevada presented the drug utilization.</li><li>• Dr. Tom Beranek with Silver Summit Health Plan presented the drug utilization.</li><li>• Dr. Jimmy Tran with Molina Healthcare presented the drug utilization.</li><li>• Dr. Kodi Izuora with Anthem presented the drug utilization.</li></ul>																													
iii) Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked if the board members had any comments.</p> <p>No comments were made.</p>																													
iv) Proposed adoption of updated prior authorization criteria.	<p>Board Member England moved to approve the criteria as presented by Prime Therapeutics, and Board Member Jessica Cate seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
d) <b>For Possible Action:</b> Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>Tonmya (cyclobenzaprine SL)</b> .																														

i) <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comments were called for, and the phone lines were opened.  No public comment was provided.																													
ii) Presentation of utilization and clinical information.	Dr. Mishra reviewed the proposed criteria presented in the binder for Tonmya (cyclobenzaprine SL)  <ul style="list-style-type: none"><li>• Dr. Jason Crecco with Health Plan of Nevada presented the drug utilization.</li><li>• Dr. Tom Beranek with Silver Summit Health Plan presented the drug utilization.</li><li>• Dr. Jimmy Tran with Molina Healthcare presented the drug utilization.</li><li>• Dr. Kodi Izuora with Anthem presented the drug utilization.</li></ul>																													
iii) Discussion by Board and review of utilization data.	Chairperson Wheeler asked if the board members had any comments.  No comment was provided.																													
iv) Proposed adoption of updated prior authorization criteria.	Vice Chair Adeolokun moved to approve the criteria as presented by Prime Therapeutics, and Chairperson Wheeler seconded the motion.  A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):  <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											

e) <b>For Possible Action:</b> Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>Neurokinin-3 Antagonists and Combinations</b> .		
i) <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>	
ii) Presentation of utilization and clinical information.	<p>Dr. Mishra reviewed the proposed criteria presented in the binder for Neurokinin-3 Antagonists and Combinations.</p> <ul style="list-style-type: none"> <li>• Dr. Jason Crecco with Health Plan of Nevada presented the drug utilization.</li> <li>• Dr. Tom Beranek with Silver Summit Health Plan presented the drug utilization.</li> <li>• Dr. Jimmy Tran with Molina Healthcare presented the drug utilization.</li> <li>• Dr. Kodi Izuora with Anthem presented the drug utilization.</li> </ul>	
iii) Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked if the board members had any comments.</p> <p>No comments were made.</p>	

iv) Proposed adoption of updated prior authorization criteria.	<p>Board Member England moved to approve the criteria as presented by Prime Therapeutics, and Vice Chair Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
f) <b>For Possible Action:</b> Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>Duchenne Muscular Dystrophy (DMD) Agents.</b>																														
i) <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>Public comment was provided by Elaine Dong Clinical Pharmacist with PTC Therapeutics Medical Affairs for Emflaza (deflazacort).</p> <p>Public comment was provided by Brain Denger with Parent Project Muscular Dystrophy.</p> <p>Public comment was provided by Dr. Craig McDonald with University of California, Davis Medical Center in Sacramento, California for Skipping Therapies, Exondys 51, Vyondys 53, Amondys 45and Viltepso.</p>																													

ii) Presentation of utilization and clinical information.	<p>Dr. Mishra reviewed the proposed criteria presented in the binder for Duchenne Muscular Dystrophy (DMD) Agents.</p> <ul style="list-style-type: none"><li>• Dr. Jason Crecco with Health Plan of Nevada presented the drug utilization.</li><li>• Dr. Tom Beranek with Silver Summit Health Plan presented the drug utilization.</li><li>• Dr. Jimmy Tran with Molina Healthcare presented the drug utilization.</li><li>• Dr. Kodi Izuora with Anthem presented the drug utilization.</li></ul>																													
iii) Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked if the board members had any comments.</p> <p>No comments were made.</p>																													
iv) Proposed adoption of updated prior authorization criteria.	<p>Board Member Crystal Casteneda moved to approve the criteria as presented by Prime Therapeutics, and Board Member Tran seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											

g) For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>Topical Androgens</b> .		
i) Public comment on proposed clinical prior authorization criteria.	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>	
ii) Presentation of utilization and clinical information.	<p>Dr. Mishra reviewed the proposed criteria presented in the binder for Topical Androgens.</p> <ul style="list-style-type: none"> <li>• Dr. Jason Crecco with Health Plan of Nevada presented the drug utilization.</li> <li>• Dr. Tom Beranek with Silver Summit Health Plan presented the drug utilization.</li> <li>• Dr. Jimmy Tran with Molina Healthcare presented the drug utilization.</li> <li>• Dr. Kodi Izuora with Anthem presented the drug utilization.</li> </ul>	
iii) Discussion by board and review of utilization data.	<p>Chairperson Wheeler asked if the board members had any comments.</p> <p>No comments were made.</p>	
iv) Proposed adoption of updated prior authorization criteria.	<p>Board Member England moved to approve the criteria as presented by Prime Therapeutics, and Vice Chair Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <p style="text-align: right;">Yes    No    Abst.</p>	

	<ul style="list-style-type: none"> <li>• Jennifer Wheeler, Pharm.D., Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Netochi Adeolokun, Pharm.D., Vice-Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Crystal Castaneda, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Jessica Cate, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Dave England, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> </ul>	
h) For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>Criteria updates per Food and Drug Administration (FDA) Label expansions.</b>		
i) Public comment on proposed clinical prior authorization criteria.	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>	
ii) Presentation clinical information.	Dr. Mishra reviewed the recent updates made to clinical prior authorization criteria per FDA approved label expansions or revisions- Valtoco (diazepam), Opzelura (ruxolitinib), Linzess (linaclotide), PCSK-9 Inhibitors.	
<b>5) Board Requested Reports</b>		
<b>Opioid Utilization Reports:</b> <ul style="list-style-type: none"> <li>i) Opioid Trends</li> <li>ii) Top Members</li> <li>iii) Top Prescribers</li> <li>iv) Top Pharmacies</li> </ul>	<ul style="list-style-type: none"> <li>• Dr. Mishra presented opioid utilization reports.</li> <li>• Dr. Crecco presented opioid utilization reports.</li> <li>• Dr. Beranek presented opioid utilization reports.</li> <li>• Dr. Tran presented opioid utilization reports.</li> <li>• Dr. Izuora presented opioid utilization reports.</li> </ul>	

<b>Comments from Board Members regarding the Opioid Utilization Reports.</b>	<p>Chairperson Wheeler asked for comments from board members regarding Opioid Reports.</p> <p>Board Member Castaneda provided comment.</p>	
<b>6) Standard DUR Reports:</b> i) Top 10 Therapeutic Classes ii) ProDUR Paid Claims Savings Report iii) RetroDUR DUR Initiatives	<ul style="list-style-type: none"> <li>• Dr. Mishra presented Standard DUR Reports.</li> <li>• Dr. Crecco presented Standard DUR Reports.</li> <li>• Dr. Beranek presented Standard DUR Reports.</li> <li>• Dr. Tran presented Standard DUR Reports.</li> <li>• Dr. Izuora presented Standard DUR Reports.</li> </ul>	
<b>7) Physician Administered Drugs</b>		
a) <b>For Possible Action:</b> Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>Physician Administered Drug</b>	Aflibercept Bavencio Bevacizumab_ONCO Darzalex_IV Darzalex_SQ Denosumab GCSF_LA Imfinzi IVIG Jemperli Keytruda_IV Libtayo Ocrevus_IV Opdivo_IV Paclitaxel Albumin-Bound Pemetrexed Tecentriq_IV Trastuzumab_IV Yervoy Zynlonta	

i) <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comments were called for, and the phone lines were opened.  No public comments were provided.																													
ii) Presentation of utilization and clinical information	Dr. Victoria Facchini reviewed the proposed criteria presented in the binder for Physician Administered Drugs (PAD).																													
iii) Proposed adoption of updated prior authorization criteria.	<p>Vice-Chair Adeolokun moved to approve the criteria as presented by Prime Therapeutics, and Board Member Castaneda seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
9) Closing Discussion																														
a) Public Comment	Telephonic and web comments were called for, and the phone lines were opened.  No public comments were provided.																													

b) Date and location of the next meeting.	Chairperson Wheeler stated the next meeting is scheduled for April 16, 2026.  <b>Location:</b> Hilton Garden Inn, Reno 9920 Double R Blvd Reno, NV 89521  Meeting adjourned at 2:37 pm	
---	---	--

**Attachment A – Members of the Public in Attendance**

Stefanie Abraham	Kristin Duffey	Michael Foster	Tracey Elizabeth Turner
Lori M Austin	Georgette Dzwilewski	Michael Pazirandeh	Valerie D Ng
Blaize, Jonathan	Ashlee Eltayeb	Miranda Ryzenman	Melanie L Wahrenberger
Brian Denger	Eric Alonzo	Nirmal Ghuman	Zoë Houghton
Cade Grogan	Adam Furman	Jenn Paschke	Ryan Roa
Carole Eisner	George Homs	Ashlee Phillips	Lee Stout
Cheryl Donahue	Ghuman, Nirmal	Lisa Pulver	Kenneth Garcia
Chris Gilbert	David Gross	Rianna White	Stuart Pappas
Craig McDonald	Joan Schindler	Richard Junk	Kristin Clark
Craig Sexton	Richard E Junk	Ryan Miller	Cynthia Martin
Daniel Monahan	Alexandra Kaiser	Sabrina Schnur	Sam Elsofky
David Nguyen	Lea Cartwright	Shawn Akey	
Dg	Amy Levin	Stephanie Kennedy	
Elaine Dong	Lisa Glick	Pam Storey	
Christine Dube	Lori Howarth	Tray Abney	

**Attachment B – Submitted Written Comment**

None Written Comments Submitted